Equities Analysts Set Expectations for ADCT Q1 Earnings

ADC Therapeutics SA (NYSE:ADCT) – Research analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for shares of ADC Therapeutics in a research report issued on Monday, March 31st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.39) for the quarter, up from their prior estimate of ($0.41). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for ADC Therapeutics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.62) EPS.

A number of other brokerages also recently commented on ADCT. Cantor Fitzgerald reiterated an “overweight” rating on shares of ADC Therapeutics in a research report on Friday, March 7th. Stephens lifted their price target on ADC Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. Finally, Guggenheim dropped their price objective on shares of ADC Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a report on Monday, March 31st. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $7.75.

ADC Therapeutics Price Performance

ADCT opened at $1.19 on Thursday. The firm has a market capitalization of $117.41 million, a price-to-earnings ratio of -0.50 and a beta of 1.55. The company’s 50 day simple moving average is $1.62 and its two-hundred day simple moving average is $2.20. ADC Therapeutics has a 1-year low of $1.14 and a 1-year high of $5.38.

ADC Therapeutics (NYSE:ADCT) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.06. The business had revenue of $19.00 million during the quarter, compared to analysts’ expectations of $19.01 million.

Institutional Investors Weigh In On ADC Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Redmile Group LLC increased its position in shares of ADC Therapeutics by 2.6% during the 3rd quarter. Redmile Group LLC now owns 15,669,217 shares of the company’s stock worth $49,358,000 after purchasing an additional 400,000 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in ADC Therapeutics by 164.1% during the third quarter. JPMorgan Chase & Co. now owns 78,813 shares of the company’s stock worth $248,000 after buying an additional 48,976 shares during the period. Platinum Investment Management Ltd. increased its position in shares of ADC Therapeutics by 11.6% during the fourth quarter. Platinum Investment Management Ltd. now owns 1,612,556 shares of the company’s stock valued at $3,209,000 after acquiring an additional 168,040 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of ADC Therapeutics by 10.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 194,258 shares of the company’s stock valued at $612,000 after acquiring an additional 18,796 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of ADC Therapeutics by 15.6% in the 3rd quarter. Geode Capital Management LLC now owns 953,171 shares of the company’s stock worth $3,002,000 after acquiring an additional 128,454 shares during the last quarter. Hedge funds and other institutional investors own 41.10% of the company’s stock.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.